Answers are grounded in this paper and cite their sources.
Randomized clinical trial demonstrates consistent immunogenicity and no new safety signals with NVX-CoV2373 in adults, supporting its use as a booster dose.
NVX-CoV2373 showed consistent immunogenicity between lots, with no new safety signals identified. Use of NVX-CoV2373 as a booster dose (first or later) is supported.
No takes yet. Share an insight, caveat, or question.
Raiser et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: